Free Trial

Zimmer Biomet (ZBH) Stock Forecast & Price Target

$111.46
+0.41 (+0.37%)
(As of 07/18/2024 ET)

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 17 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 1 has given a sell rating, 10 have given a hold rating, and 6 have given a buy rating for ZBH.

Consensus Price Target

$129.53
16.21% Upside
High Forecast$155.00
Average Forecast$129.53
Low Forecast$115.00

According to the 17 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $129.53. The highest price target for ZBH is $155.00, while the lowest price target for ZBH is $115.00. The average price target represents a forecasted upside of 16.21% from the current price of $111.46.

TypeCurrent Forecast
7/19/23 to 7/18/24
1 Month Ago
6/19/23 to 6/18/24
3 Months Ago
4/20/23 to 4/19/24
1 Year Ago
7/19/22 to 7/19/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
10 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$129.53$133.75$139.39$144.00
Forecasted Upside16.21% Upside12.04% Upside12.55% Upside10.83% Upside
Get Zimmer Biomet Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zimmer Biomet Stock vs. The Competition

TypeZimmer BiometMedical CompaniesS&P 500
Consensus Rating Score
2.29
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.28% Upside1,347.42% Upside9.16% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/16/2024Truist Financial
1 of 5 stars
 Lower TargetHold ➝ Hold$130.00 ➝ $117.00+9.05%
7/15/2024Morgan Stanley
3 of 5 stars
 Lower TargetEqual Weight ➝ Equal Weight$130.00 ➝ $120.00+12.21%
7/10/2024Citigroup
3 of 5 stars
 Lower TargetNeutral ➝ Neutral$134.00 ➝ $120.00+12.25%
7/2/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetIn-Line ➝ In-Line$130.00 ➝ $115.00+8.74%
7/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. O'brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$140.00 ➝ $115.00+5.96%
5/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$130.00 ➝ $125.00+9.39%
5/30/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$129.00+12.04%
5/21/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+25.89%
5/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$150.00 ➝ $155.00+29.43%
2/23/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Hold$130.00+0.61%
2/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$115.00 ➝ $125.00+1.90%
2/9/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$140.00+15.14%
1/3/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$133.00 ➝ $137.00+13.70%
11/13/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$160.00 ➝ $140.00+31.14%
10/20/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$120.00+14.56%
8/28/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$139.00+20.62%
8/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$116.00 ➝ $125.00-3.84%
5/18/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/18/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$160.00 ➝ $165.00+22.19%
5/3/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/3/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$121.00 ➝ $147.00+4.13%
5/3/2023FIG Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral
5/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral
5/3/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$145.00 ➝ $172.00+20.27%
5/3/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$136.00 ➝ $152.00+6.29%
3/31/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Hold$115.00 ➝ $130.00+2.56%
2/6/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$125.00 ➝ $140.00+8.15%
11/23/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$116.00 ➝ $124.00+7.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:43 PM ET.

ZBH Forecast - Frequently Asked Questions

What is Zimmer Biomet's forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $129.53, with a high forecast of $155.00 and a low forecast of $115.00.

Should I buy or sell Zimmer Biomet stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There is currently 1 sell rating, 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.

Does Zimmer Biomet's stock price have much upside?

According to analysts, Zimmer Biomet's stock has a predicted upside of 13.11% based on their 12-month stock forecasts.

Has Zimmer Biomet been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade and 1 downgrade by analysts.

What analysts cover Zimmer Biomet?

Zimmer Biomet has been rated by research analysts at Argus, Barclays, Citigroup, Evercore ISI, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, The Goldman Sachs Group, and Truist Financial in the past 90 days.

Do Wall Street analysts like Zimmer Biomet more than its competitors?

Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.


This page (NYSE:ZBH) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners